MaaT Pharma publishes its 2023 half-year results and provides an update on its activities:
• The ARES study on MaaT013 has reached the threshold of patients required to schedule the DSMB review scheduled for the beginning of the fourth quarter of 2023
• The European Medicines Agency (EMA) has granted orphan drug status to MaaT033 aimed at improving the overall survival of patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT)
• The first patient was treated in the IASO Phase 1b pilot study (NCT05889572) in amyotrophic lateral sclerosis (ALS) with MaaT033
• End of construction of the production factory, completed in 12 months, in partnership with Skyepharma and relocation of the MaaT Pharma production and development teams to the 1600m² of the new factory
• As of June 30, 2023, the cash and cash equivalents position amounted to €35.1 million, with an expected horizon during the second quarter of 2024
• Turnover for the first half was 1.4 million euros
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]